PCSK9 and Hepatic steatosis: This suggested that the deficiency of PCSK9 drastically diminished the levels of tissue cholesterol and provided resistance to hepatic steatosis.122 The initial evidence of PCSK9 contributing to the growth of atherosclerosis was observed in experimental mice fed HCD for 15 weeks.